C. Karlovich

发表

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements

Jessica L. Larson, Brian C. Haynes, T. Godfrey, 2019, The Journal of molecular diagnostics : JMD.

Functional Roles for the Pleckstrin and Dbl Homology Regions in the Ras Exchange Factor Son-of-sevenless (*)

U. Banerjee, M. Czech, L. Kozma, 1995, The Journal of Biological Chemistry.

In vivo functional analysis of the Ras exchange factor son of sevenless.

U. Banerjee, M. Czech, A. Daga, 1995, Science.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.

P. Angenendt, H. Wakelee, L. Sequist, 2013 .

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.

Alina M. Hamilton, L. Staudt, E. Kohn, 2020, Cancer cell.

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

H. Wakelee, L. Sequist, S. Ou, 2015 .

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

M. Erlander, J. Neal, H. Wakelee, 2016 .

Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors

P. M. Williams, S. Mueller, R. Packer, 2022, npj Precision Oncology.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Maximilian Diehn, Aaron M. Newman, 2016, Nature Communications.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Cell‐Free DNA Next‐Generation Sequencing Prediction of Response and Resistance to Third‐Generation EGFR Inhibitor

E. Helman, R. Camidge, T. Harding, 2018, Clinical lung cancer.

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network

P. A. Futreal, Daoud M. Meerzaman, S. Gabriel, 2020, Clinical Cancer Research.

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Yvonne A. Evrard, L. McShane, J. Doroshow, 2021, Journal of Translational Medicine.

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components

J. Doroshow, A. Chen, R. Parchment, 2022, OncoTargets and therapy.

OTT_A_278092 165..180

J. Doroshow, A. Chen, R. Parchment, 2022 .

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients

D. Grimm, V. Tadigotla, L. Raez, 2019, Oncotarget.

Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients

J. Healy, D. Grimm, B. Tannous, 2018, Clinical Cancer Research.

Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health

C. Paweletz, K. Cole, J. Barrett, 2021, JCO precision oncology.

Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for EGFR and MET gene copy number measurements

S. Lund, J. Almeida, K. Cole, 2019, Clinical chemistry and laboratory medicine.

The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study.

L. Staudt, E. Kohn, D. Wheeler, 2020, Journal of the National Cancer Institute.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Aaron M. Newman, Kathleen A. Durkin, 2016, Nature Communications.

The Son of sevenless gene product: a putative activator of Ras.

U. Banerjee, C. Dasgupta, C. Karlovich, 1992, Science.

Clinical Applications of Next-Generation Sequencing in Precision Oncology

P. M. Williams, C. Karlovich, P. Williams, 2019, Cancer journal.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

H. Wakelee, L. Sequist, D. Grimm, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

David J. Sims, J. Foster, R. Simon, 2021, JCO precision oncology.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

Genetic dissection of a neurodevelopmental pathway: Son of sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases

U. Banerjee, C. Karlovich, R. Rogge, 1991, Cell.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

H. Kohrt, R. Pierce, H. Maecker, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A putative Drosophila homolog of the Huntington's disease gene.

R. Myers, M. Scott, M. Fish, 1999, Human molecular genetics.

Characterization of the Huntington's disease (HD) gene homologue in the zebrafish Danio rerio.

L. Ramirez, D. Stainier, R. John, 1998, Gene.

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

H. Kohrt, H. Maecker, J. Yearley, 2018, Blood.

A longitudinal study of gene expression in healthy individuals

P. Mcloughlin, L. Steiner, J. Caulfield, 2009, BMC Medical Genomics.

Patterning of cells in the Drosophila eye by Lozenge, which shares homologous domains with AML1.

U. Banerjee, K. Dumstrei, A. Daga, 1996, Genes & development.

Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficienc

S. Chowdhury, C. Ryan, C. Karlovich, 2017 .

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Y. Shyr, M. Berens, R. Bindra, 2019, Blood.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

H. Wakelee, L. Sequist, D. Grimm, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Yvonne A. Evrard, L. McShane, J. Doroshow, 2021, Journal of Translational Medicine.

Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.

A. Iafrate, J. Sklar, K. Flaherty, 2019, Journal of Clinical Oncology.

MyoD is required for myogenic stem cell function in adult skeletal muscle.

P. Silver, M. Rudnicki, U. Banerjee, 1996, Genes & development.

Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs

Tina Koestler, H. Wakelee, L. Sequist, 2015 .

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.